Inhaltsbereich
| 54 Einträge | 1, 2, 3 › » |
Seite 1 / 3
 Druckansicht
|
| Gaining momentum: New options and opportunities for the treatment of advanced melanoma. |
| Michielin O, Hoeller C |
| Cancer treatment reviews. 2015 Jun 4. pii: S0305-7372(15)00122-X. doi: 10.1016/j.ctrv.2015.05.012 |
| PMID: 26096079 |
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. |
| Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J |
| The Lancet. Oncology. 2015 Mar 18. pii: S1470-2045(15)70076-8. doi: 10.1016/S1470-2045(15)70076-8 |
| PMID: 25795410 |
| IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma. |
| Probst M, Hoeller C, Ferenci P, Staettermayer AF, Beinhardt S, Pehamberger H, Kittler H, Grabmeier-Pfistershammer K |
| PloS one. 2014 Nov 12. doi: 10.1371/journal.pone.0112613. pii: PONE-D-14-33575. pmc: PMC4229256 |
| PMID: 25389973 |
| Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. |
| Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R |
| European journal of cancer (Oxford, England : 1990). 2013 Oct 29. pii: S0959-8049(13)00876-9. doi: 10.1016/j.ejca.2013.09.014 |
| PMID: 24183461 |
| Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis. |
| Edelhauser G, Schicher N, Berzaczy D, Beitzke D, Höeller C, Lammer J, Funovics M |
| AJR. American journal of roentgenology. 2012 Nov 21. pii: 199/6/1387. doi: 10.2214/AJR.11.7748 |
| PMID: 23169735 |
| Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma- a single centre experience. |
| Schicher N, Edelhauser G, Harmankaya K, Schindler K, Gleiss A, Pehamberger H, Hoeller C |
| Journal of the European Academy of Dermatology and Venereology : JEADV. 2012 Oct 12. doi: 10.1111/jdv.12006 |
| PMID: 23057648 |
| A rare case of primary rhabdoid melanoma of the urinary bladder treated with ipilimumab, an anti-CTLA 4 monoclonal antibody. |
| Schindler K, Schicher N, Kunstfeld R, Pehamberger H, Toepker M, Haitel A, Hoeller C, Harmankaya K |
| Melanoma research. 2012 Jul 6. doi: 10.1097/CMR.0b013e32835566c0 |
| PMID: 22713795 |
| Erlotinib and bevacizumab have synergistic activity against melanoma. |
| Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 May 15. pii: 1078-0432.CCR-08-2407. doi: 10.1158/1078-0432.CCR-08-2407 |
| PMID: 19447871 |
| Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. |
| Heere-Ress E, Boehm J, Thallinger C, Hoeller C, Wacheck V, Birner P, Wolff K, Pehamberger H, Jansen B |
| The Journal of investigative dermatology. 2005 Aug 15. pii: JID23830. doi: 10.1111/j.0022-202X.2005.23830.x |
| PMID: 16098027 |
| Clusterin regulates drug-resistance in melanoma cells. |
| Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, Sexl V, Wacheck V, Gleave ME, Pehamberger H, Jansen B |
| The Journal of investigative dermatology. 2005 Jun 15. pii: JID23720. doi: 10.1111/j.0022-202X.2005.23720.x |
| PMID: 15955107 |
| The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. |
| Hoeller C, Thallinger C, Pratscher B, Bister MD, Schicher N, Loewe R, Heere-Ress E, Roka F, Sexl V, Pehamberger H |
| The Journal of investigative dermatology. 2005 Jun 15. pii: JID23685. doi: 10.1111/j.0022-202X.2005.23685.x |
| PMID: 15955106 |
| MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. |
| Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, Macfelda K |
| Magnetic resonance imaging. 2004 Jul 5. doi: 10.1016/j.mri.2004.01.050. pii: S0730725X04000700 |
| PMID: 15234453 |
| Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? |
| Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM |
| PloS one. 2015 Oct 1. doi: 10.1371/journal.pone.0139438. pii: PONE-D-14-51511. pmc: PMC4591284 |
| PMID: 26426340 |
| Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. |
| Hoeller C, Michielin O, Ascierto PA, Szabo Z, Blank CU |
| Cancer immunology, immunotherapy : CII. 2016 Jul 2. doi: 10.1007/s00262-016-1860-3. pii: 10.1007/s00262-016-1860-3 |
| PMID: 27372293 |
| Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. |
| Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen JB, Long GV, Blank CU |
| Oncoimmunology. 2016 Oct 14. doi: 10.1080/2162402X.2016.1238557. pii: 1238557 |
| PMID: 28123875 |
| Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. |
| Dummer R, Hoeller C, Gruter IP, Michielin O |
| Cancer immunology, immunotherapy : CII. 2017 Feb 25. doi: 10.1007/s00262-017-1967-1. pii: 10.1007/s00262-017-1967-1 |
| PMID: 28238174 |
| More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. |
| Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C |
| European journal of cancer (Oxford, England : 1990). 2017 Mar 2. pii: S0959-8049(17)30069-2. doi: 10.1016/j.ejca.2017.01.012 |
| PMID: 28264791 |
| Beyond the BRAF(V)(600E) hotspot - Biology and clinical implications of rare BRAF gene mutations in melanoma patients. |
| Richtig G, Hoeller C, Kashofer K, Aigelsreiter A, Heinemann A, Kwong LN, Pichler M, Richtig E |
| The British journal of dermatology. 2017 Mar 9. doi: 10.1111/bjd.15436 |
| PMID: 28278349 |
| Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. |
| Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M |
| The Lancet. Oncology. 2017 Mar 27. pii: S1470-2045(17)30231-0. doi: 10.1016/S1470-2045(17)30231-0 |
| PMID: 28359784 |
| Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. |
| Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 3. doi: 10.1200/JCO.2016.71.8023 |
| PMID: 28671856 |
| 54 Einträge | 1, 2, 3 › » |
Seite 1 / 3
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
